Experimental drug targets rare genitourinary cancers in new trial
NCT ID NCT07716917
First seen Jul 21, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with two rare types of cancer: papillary renal carcinoma and less common forms of bladder cancer. The drug is given by IV every two weeks for up to three years. The main goal is to see how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody-drug conjugate called sacituzumab tirumotecan
- What this could lead to
- If successful, this could offer a new treatment option for rare and hard-to-treat kidney and bladder cancers that currently have few effective therapies.
- What could go wrong
- This is an early-phase, single-arm trial with no placebo group, so results may not prove the drug works better than existing options. Side effects from the drug could also limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLARY RENAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••